On Invalid Date, Genelux (NASDAQ: GNLX) reported Q4 2023 earnings per share (EPS) of -$0.25, up 34.21% year over year. Total Genelux earnings for the quarter were -$6.77 million. In the same quarter last year, Genelux's earnings per share (EPS) was -$0.38.
As of Q2 2024, Genelux's earnings has grown year over year. Genelux's earnings in the past year totalled -$28.30 million.
What was GNLX's revenue last quarter?
On Invalid Date, Genelux (NASDAQ: GNLX) reported Q4 2023 revenue of $0.00 up 100% year over year. In the same quarter last year, Genelux's revenue was $68.00 thousand.
What was GNLX's revenue growth in the past year?
As of Q2 2024, Genelux's revenue has grown -98.46% year over year. This is 246.87 percentage points lower than the US Biotechnology industry revenue growth rate of 148.4%. Genelux's revenue in the past year totalled $170.00 thousand.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.